{
    "id": "52831935",
    "text": "Taselisib (development code: GDC-0032) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor targeting the p110\u03b1 protein product of the phosphoinositide 3-kinase gene, PIK3CA. Taselisib is in phase III clinical trials for treatment of metastatic breast cancer (\"Sandpiper\") and non-small cell lung cancer (\"Lung-MAP\"). ==References== Category:Experimental cancer drugs Category:Phosphoinositide 3-kinase inhibitors Category:Propionamides Category:Benzoxazepines ",
    "title": "Taselisib"
}